• Je něco špatně v tomto záznamu ?

Molecular design, synthesis and anticancer activity of new thiopyrano[2,3-d]thiazoles based on 5-hydroxy-1,4-naphthoquinone (juglone)

I. Ivasechko, A. Lozynskyi, J. Senkiv, P. Roszczenko, Y. Kozak, N. Finiuk, O. Klyuchivska, N. Kashchak, N. Manko, Z. Maslyak, D. Lesyk, A. Karkhut, S. Polovkovych, R. Czarnomysy, O. Szewczyk, A. Kozytskiy, O. Karpenko, D. Khyluk, A. Gzella, K....

. 2023 ; 252 (-) : 115304. [pub] 20230324

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010486

A series of 11-substituted 9-hydroxy-3,5,10,11-tetrahydro-2H-benzo[6,7]thiochromeno[2,3-d][1,3]thiazole-2,5,10-triones 3.1-3.13 were synthesized via hetero-Diels-Alder reaction of 5-ene-4-thioxo-2-thiazolidinones and 5-hydroxy-1,4-naphthoquinone (juglone). The structure of newly synthesized compounds was established by means of spectral data and a single-crystal X-ray diffraction analysis. The synthesized compounds were tested on a panel of cell lines representing different types of cancer as well as normal and pseudonormal cells and peripheral human blood lymphocytes. Compound 3.10 was found to be the most active derivative, exhibiting a cytotoxic effect similar to doxorubicin's one (IC50 ranged from 0.6 to 5.98 μM), but less toxic to normal and pseudonormal cells. All synthesized compounds were able to interact with DNA, although their anticancer activity did not correlate with the potency of interaction with DNA. The status of p53 in colorectal cancer cells correlated with the activity of the synthesized derivatives 3.1, 3.7, and 3.10. Compound 3.10 did not have an acute toxic effect on the body of С57BL/6 mice, unlike the well-known anticancer drug doxorubicin, which was used as a positive control. The injection of 3.10 (20 mg/kg) to mice had no effect on the counts of leukocytes, erythrocytes, platelets and hemoglobin level in their blood, in contrast to doxorubicin, which caused anemia and leukopenia, indicating bio-tolerance of 3.10in vivo.

Department of Biotechnology and Cell Biology Medical College University of Information Technology and Management in Rzeszow Sucharskiego 2 35 225 Rzeszow Poland

Department of Biotechnology Faculty of Pharmacy Medical University of Bialystok Jana Kilińskiego 1 15 089 Bialystok Poland

Department of Organic Chemistry Faculty of Pharmacy with Medical Analytics Division Medical University of Lublin 4A Chodzki Lublin 20 093 Poland

Department of Organic Chemistry Poznan University of Medical Sciences Grunwaldzka 6 60 780 Poznan Poland

Department of Pharmaceutical Organic and Bioorganic Chemistry Danylo Halytsky Lviv National Medical University Pekarska 69 Lviv 79010 Ukraine

Department of Synthesis and Technology of Drugs Faculty of Pharmacy Medical University of Bialystok Jana Kilińskiego 1 15 089 Bialystok Poland

Department of Technology of Biologically Active Substances Pharmacy and Biotechnology Lviv Polytechnic National University Bandera 12 Lviv 79013 Ukraine

Enamine Ltd Chervonotkatska Street 78 Kyiv 02094 Ukraine

Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine General Chuprynky 45 Lviv 79044 Ukraine

Institute of Cell Biology of National Academy of Sciences of Ukraine Drahomanov14 16 Lviv 79005 Ukraine

Institute of Molecular and Translational Medicine Faculty of Medicine and Dentistry Palacky University and University Hospital in Olomouc Hnevotinska 5 77900 Olomouc Czech Republic

L 5 Pysarzhevsky Institute of Physical Chemistry National Academy of Sciences of Ukraine Nauky Avenue 31 Kyiv 03028 Ukraine

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010486
003      
CZ-PrNML
005      
20230801132445.0
007      
ta
008      
230718s2023 fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2023.115304 $2 doi
035    __
$a (PubMed)37001390
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Ivasechko, Iryna $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
245    10
$a Molecular design, synthesis and anticancer activity of new thiopyrano[2,3-d]thiazoles based on 5-hydroxy-1,4-naphthoquinone (juglone) / $c I. Ivasechko, A. Lozynskyi, J. Senkiv, P. Roszczenko, Y. Kozak, N. Finiuk, O. Klyuchivska, N. Kashchak, N. Manko, Z. Maslyak, D. Lesyk, A. Karkhut, S. Polovkovych, R. Czarnomysy, O. Szewczyk, A. Kozytskiy, O. Karpenko, D. Khyluk, A. Gzella, K. Bielawski, A. Bielawska, P. Dzubak, S. Gurska, M. Hajduch, R. Stoika, R. Lesyk
520    9_
$a A series of 11-substituted 9-hydroxy-3,5,10,11-tetrahydro-2H-benzo[6,7]thiochromeno[2,3-d][1,3]thiazole-2,5,10-triones 3.1-3.13 were synthesized via hetero-Diels-Alder reaction of 5-ene-4-thioxo-2-thiazolidinones and 5-hydroxy-1,4-naphthoquinone (juglone). The structure of newly synthesized compounds was established by means of spectral data and a single-crystal X-ray diffraction analysis. The synthesized compounds were tested on a panel of cell lines representing different types of cancer as well as normal and pseudonormal cells and peripheral human blood lymphocytes. Compound 3.10 was found to be the most active derivative, exhibiting a cytotoxic effect similar to doxorubicin's one (IC50 ranged from 0.6 to 5.98 μM), but less toxic to normal and pseudonormal cells. All synthesized compounds were able to interact with DNA, although their anticancer activity did not correlate with the potency of interaction with DNA. The status of p53 in colorectal cancer cells correlated with the activity of the synthesized derivatives 3.1, 3.7, and 3.10. Compound 3.10 did not have an acute toxic effect on the body of С57BL/6 mice, unlike the well-known anticancer drug doxorubicin, which was used as a positive control. The injection of 3.10 (20 mg/kg) to mice had no effect on the counts of leukocytes, erythrocytes, platelets and hemoglobin level in their blood, in contrast to doxorubicin, which caused anemia and leukopenia, indicating bio-tolerance of 3.10in vivo.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a thiazoly $x chemie $7 D013844
650    12
$a protinádorové látky $x chemie $7 D000970
650    12
$a naftochinony $x farmakologie $7 D009285
650    _2
$a doxorubicin $x farmakologie $7 D004317
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a molekulární struktura $7 D015394
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a proliferace buněk $7 D049109
650    _2
$a nádorové buněčné linie $7 D045744
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lozynskyi, Andrii $u Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
700    1_
$a Senkiv, Julia $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
700    1_
$a Roszczenko, Piotr $u Department of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
700    1_
$a Kozak, Yuliia $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
700    1_
$a Finiuk, Nataliya $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
700    1_
$a Klyuchivska, Olga $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
700    1_
$a Kashchak, Nataliya $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
700    1_
$a Manko, Nazar $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine
700    1_
$a Maslyak, Zvenyslava $u Institute of Blood Pathology and Transfusion Medicine of National Academy of Medical Sciences of Ukraine, General Chuprynky 45, Lviv, 79044, Ukraine
700    1_
$a Lesyk, Danylo $u Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine
700    1_
$a Karkhut, Andriy $u Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv Polytechnic National University, Bandera 12, Lviv, 79013, Ukraine
700    1_
$a Polovkovych, Svyatoslav $u Department of Technology of Biologically Active Substances, Pharmacy and Biotechnology, Lviv Polytechnic National University, Bandera 12, Lviv, 79013, Ukraine
700    1_
$a Czarnomysy, Robert $u Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
700    1_
$a Szewczyk, Olga $u Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
700    1_
$a Kozytskiy, Andriy $u Enamine Ltd, Chervonotkatska Street 78, Kyiv, 02094, Ukraine; L.V. Pysarzhevsky Institute of Physical Chemistry, National Academy of Sciences of Ukraine, Nauky Avenue 31, Kyiv, 03028, Ukraine
700    1_
$a Karpenko, Olexandr $u Enamine Ltd, Chervonotkatska Street 78, Kyiv, 02094, Ukraine
700    1_
$a Khyluk, Dmytro $u Department of Organic Chemistry, Faculty of Pharmacy with Medical Analytics Division, Medical University of Lublin, 4A Chodzki, Lublin, 20-093, Poland
700    1_
$a Gzella, Andrzej $u Department of Organic Chemistry, Poznan University of Medical Sciences, Grunwaldzka 6, 60-780, Poznan, Poland
700    1_
$a Bielawski, Krzysztof $u Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
700    1_
$a Bielawska, Anna $u Department of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089, Bialystok, Poland
700    1_
$a Dzubak, Petr $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 77900, Olomouc, Czech Republic
700    1_
$a Gurska, Sona $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 77900, Olomouc, Czech Republic
700    1_
$a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 77900, Olomouc, Czech Republic
700    1_
$a Stoika, Rostyslav $u Institute of Cell Biology of National Academy of Sciences of Ukraine, Drahomanov14/16, Lviv, 79005, Ukraine. Electronic address: stoika.rostyslav@gmail.com
700    1_
$a Lesyk, Roman $u Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, Lviv, 79010, Ukraine; Department of Biotechnology and Cell Biology, Medical College, University of Information Technology and Management in Rzeszow, Sucharskiego 2, 35-225, Rzeszow, Poland. Electronic address: dr_r_lesyk@org.lviv.net
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 252, č. - (2023), s. 115304
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37001390 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20230801132442 $b ABA008
999    __
$a ok $b bmc $g 1963108 $s 1196751
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 252 $c - $d 115304 $e 20230324 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...